Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NR5A2 | O00482 | 2/20 | 0.63 |
| ▸ | NR5A1 | Q13285 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.52 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327161 | 0.98 | SMN1; SMN2 (0.66) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL3502856 | 0.98 | SMN1; SMN2 (0.66) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL2021533 | 0.98 | SMN1; SMN2 (0.66) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL326877 | 0.92 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL747961 | 0.92 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL5698359 | 0.92 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL326926 | 0.92 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL672430 | 0.92 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| Trifluoromethanesulfonic Acid SCHEMBL184536 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL18628315 | 0.90 | S1PR1 (0.61) | SMN1; SMN2NR5A2NR5A1ALDH1A1SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207186-A1 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR LOADING RNA | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2024-06-27 | — | — | US | claimed |
| WO-2024119017-A1 | SYNTHETIC SINGLE STRANDED NUCLEIC ACID COMPOSITIONS AND METHODS THEREOF | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024119074-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | claimed |
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | EYEGENE INC. (KR) | 2024-05-23 | — | — | US | claimed |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | EYEGENE INC. (KR) | 2024-05-09 | — | — | US | claimed |
| EP-4356933-A1 | COMPOSITION FOR DELIVERING MODIFIED NUCLEIC ACID-CONTAINING MRNA | Eyegene, Inc. (KR) | 2024-04-24 | — | — | EP | claimed |
| US-20240115513-A1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | THE JOHNS HOPKINS UNIVERSITY | 2024-04-11 | — | — | US | claimed |
| WO-2024054020-A1 | COMPOSITION FOR DELIVERING MODIFIED NUCLEIC ACID-CONTAINING MRNA | 아이진 주식회사 | 2024-03-14 | — | — | WO | claimed |
| EP-4313003-A1 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | Recode Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4306132-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPARATION METHOD THEREFOR | Eyegene Inc. (KR) | 2024-01-17 | — | — | EP | claimed |
| EP-3247328-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PhaseRx, Inc. (US) | 2017-11-29 | — | — | EP | claimed |
| US-20170304213-A1 | Amphiphile-Polymer Particles | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-10-26 | — | — | US | claimed |
| WO-2017180917-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. (US) | 2017-10-19 | — | — | WO | claimed |
| US-9549901-B2 | Lipid-polymer hybrid particles | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-01-24 | — | — | US | claimed |
| WO-2016118697-A9 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-09-29 | — | — | WO | claimed |
| WO-2016118697-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-07-28 | — | — | WO | claimed |
| US-20130315831-A1 | LIPID-POLYMER HYBRID PARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-11-28 | — | — | US | claimed |
| EP-2654779-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | Ludwig Institute for Cancer Research, Ltd. (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012088414-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2012-06-28 | — | — | WO | claimed |
| WO-2012031205-A2 | LIPID-POLYMER HYBRID PARTICLES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | ACE2, SARS1, RBM22 | SMN1; SMN2 480/4885NR5A2 2098/4885NR5A1 3502/4885 |
| US-20240207186-A1 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR LOADING RNA | SARNP, SYNCRIP, AUP1 | SMN1; SMN2 2976/4885NR5A2 4023/4885NR5A1 3168/4885 |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | RTCB, RRP1B, PRPF6 | SMN1; SMN2 817/4885NR5A2 4748/4885NR5A1 3917/4885 |
| US-20130315831-A1 | LIPID-POLYMER HYBRID PARTICLES | LIPA, CETP, PHOSPHO1 | SMN1; SMN2 3886/4885NR5A2 4025/4885NR5A1 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.